Hot Stock: This Multibagger Micro-Cap Stock Surges 12 Per Cent After A Major US FDA Approval
In the last one year the stock has given 2 per cent returns, while in the last five years, it has given 935 per cent multibagger returns.
Venus Remedies Ltd is trading sharply higher today, up by Rs 36.95 or 11.86 per cent at Rs 348.55, as investor sentiment turned positive following a significant regulatory update.
Venus Remedies Limited, on April 17, 2025, announced that its investigational product VRP-034 has received Qualified Infectious Disease Product (QIDP) designation from the United States Food and Drug Administration (US FDA). VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, developed by Venus Medicine Research Centre (VMRC), the R&D division of Venus Remedies.
The QIDP designation, granted under the Generating Antibiotic Incentives Now (GAIN) Act, provides VRP-034 with several regulatory benefits. These benefits include eligibility for fast track designation, priority review, and an additional five years of market exclusivity upon approval in the United States.
DSIJ’s 'multibagger Pick’ service recommends well researched multibagger stocks with High Returns potential. If this interests you, download the service details here.
Key preclinical findings for VRP-034 indicate a reduction in nephrotoxicity by up to 70 per cent compared to marketed polymyxin B. Clinical use of polymyxins is often limited by nephrotoxicity, which affects up to 60 per cent of patients. VRP-034 aims to address this issue.
About Company
Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company and an injectable manufacturer. VSR is one of the largest manufacturers of meropenem antibiotics and emerging player in AMR drug in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin & wound care. The company has 1040+ marketing authorisations globally, 135+ patents and 180+ product basket which includes formulations such as injectables, tablets, and topical preparations.
In the last one year the stock has given 2 per cent returns, while in the last five years, it has given 935 per cent multibagger returns.
Investors should keep an eye on this micro-cap pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice.